[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clinically-significant-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clinically-significant-prostate-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100639284","multimodal-imaging-and-digital-pathology-for-prostate-cancer-prediction-100639284",false,"NCT07614256","Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction","A Multicenter Study of a Deep Learning Model Based on Spatial Registration of Multimodal Imaging and Digital Pathology for Predicting Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n1. Subjects who are scheduled to undergo or have undergone prostate biopsy or radical prostatectomy.\n2. Subjects who have completed standard-of-care preoperative multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS) examinations.\n3. Subjects with complete pathological diagnosis results available.\n4. Age between 40 and 90 years.\n5. Able and willing to provide written informed consent (for prospective cohort participants only).\n\nExclusion Criteria:\n\n1. Prior history of pelvic radiation therapy or radical prostatectomy.\n2. Incomplete or poor-quality mpMRI or TRUS images (e.g., motion artifacts, insufficient sequences).\n3. Concurrent other primary malignant tumors.\n4. Severe systemic diseases that may affect the evaluation of the prostate.\n5. Subjects with incomplete clinical or pathological data.\n6. Contraindications to MRI examination (e.g., incompatible metallic implants, severe claustrophobia).","MALE","40 Years","90 Years",{"count":20,"type":21},3000,"ESTIMATED","12 Years","OBSERVATIONAL","This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological whole slide images. The study is designed to achieve accurate prediction of clinically significant prostate cancer and non-invasive risk stratification. Unnecessary prostate biopsy and overdiagnosis can be reduced to support the optimization of clinical diagnosis and treatment strategies.",[26,27],"Prostate Cancer (Diagnosis)","Clinically Significant Prostate Cancer",[29,30,31,32,33,34,35,36,37],"Prostate cancer","Clinically significant prostate cancer","Multiparametric Magnetic Resonance Imaging","Transrectal ultrasound","Digital pathology","Deep learning","Artificial intelligence","Spatial registration","Risk stratification","RECRUITING","2026-05-25",{"date":41,"type":42},"2026-05-29","ACTUAL",{"date":44,"type":42},"2025-05-30",{"date":46,"type":21},"2030-12-31",{"name":48,"class":49},"Guangxi Medical University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100630842","plasma-exorna-based-liquid-biopsy-to-diagnose-clinically-significant-prostate-cancer-100630842","NCT07492927","Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n1. Blood prostate-specific antigen PSA\\>4ng\u002Fdl;\n2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.\n3. The patient is willing to undergo prostate biopsy.\n\nExclusion Criteria:\n\n1. Previous diagnosis of prostate cancer through prostate biopsy;\n2. History of other malignant tumors in the past two years;\n3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment","18 Years",{"count":59,"type":21},1700,"The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.",[27],"2026-03-19",{"date":64,"type":42},"2026-03-25",{"date":66,"type":42},"2021-03-12",{"date":68,"type":21},"2027-06-30",{"name":70,"class":49},"Xijing Hospital",10,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":71},"100605906","study-of-psma-petct-imaging-to-help-select-men-with-low-risk-prostate-cancer-for-active-surveillance-100605906","NCT07168616","Study of PSMA PET\u002FCT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance","Prospective Evaluation of Istanbul PSMA PET\u002FCT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer","I-SELECT","Inclusion Criteria:\n\n* mpMRI performed within 3 months prior to enrollment\n* Systematic or MRI-targeted prostate biopsy performed\n* Biopsy-confirmed ISUP Grade 1 low-risk PCa\n* Prostate biopsy report specifying tumor localization and number of positive cores\n* Meets AS criteria: ISUP 1, PSA ≤10 ng\u002FmL, PSAd \\>0.15 ng\u002FmL², clinical stage cT1c-T2a, ≤3 positive cores\n* Life expectancy ≥10 years\n* No prior PSMA PET imaging\n* No evidence of extra-prostatic disease on mpMRI\n* Signed informed consent for study procedures\n\nExclusion Criteria:\n\n* High-risk or unfavorable intermediate-risk PCa, or adverse histologies (neuroendocrine, ductal adenocarcinoma, basal cell carcinoma, TP53 or BRCA1\u002F2 mutations if available)\n* Prior prostate cancer treatment or prostate surgery\n* MRI evidence of extracapsular extension, seminal vesicle invasion, or nodal metastasis\n* History of pelvic radiotherapy\n* Life expectancy \\\u003C10 years\n* Severe renal impairment\n* Inability to comply with follow-up schedule",{"count":81,"type":21},201,"2 Years","This is a multicenter, prospective diagnostic accuracy study evaluating the Istanbul PSMA PET\u002FCT Criteria (IPPC) for selecting patients with biopsy-confirmed low-risk prostate cancer (ISUP Grade 1) for active surveillance (AS). The study integrates delayed Ga-68 PSMA PET\u002FCT imaging into the diagnostic pathway to refine patient stratification, minimize overtreatment and potentially reduce unnecessary biopsies and MRI, or exposing high-risk individuals to the danger of cancer progression if left untreated scans.",[85,27],"Low Risk Prostate Cancer",[87,88,89,90,91,92],"PSMA PET\u002FCT","Low risk prostate cancer","active surveillance","prostate cancer","clinically significant prostate cancer","Diagnosis of prostate cancer","2025-09-11",{"date":95,"type":42},"2025-09-15",{"date":97,"type":42},"2025-09-01",{"date":99,"type":21},"2028-06-01",{"name":101,"class":49},"Istanbul University - Cerrahpasa"]